Prolonged survival of small cell ovarian cancer-hypercalcemic type (SCCOHT): Should radiotherapy play a larger role?

Gynecologic Cancer
Session Type and Session Title: 
This abstract will not be presented at the 2015 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract Number: 


J Clin Oncol 33, 2015 (suppl; abstr e16542)
Donato Callegaro Filho, Alpa Manchandia Nick, Mark F. Munsell, Pedro T Ramirez, David Marc Gershenson, Andrea S. Dickens, Dina Patel, Patricia J. Eifel, Elizabeth D. Euscher, Kathleen M. Schmeler; Hospital Israelita Albert Einstein, São Paulo, Brazil; The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract Disclosures


Background: SCCOHT is a rare and aggressive disease. Regardless of tumor stage, most patients relapse and die of disease within two years of diagnosis. However, a small proportion of patients survive beyond two years. The aim of this study was to describe the treatment approaches in these patients with extended survival. Methods: We performed a retrospective study of 47 patients with SCCOHT evaluated at a tertiary cancer center between January 1990 and August 2014. Twelve patients (26%) were alive more than two years after diagnosis and included in this study. Medical records were reviewed for demographic information, pathologic findings, treatment regimens and outcomes. Results: Median age at diagnosis was 30 years (range, 14-43). Eight patients (67%) had stage I disease, two (16.5%) had stage II disease, and two (16.5%) had stage III disease. All patients underwent surgery. Seven (58%) received adjuvant treatment with chemotherapy alone, four (33%) received chemotherapy followed by radiotherapy and one (8%) patient received no adjuvant therapy. Five patients (42%) developed recurrent disease a median of 24 months (range, 8-125) from diagnosis. Treatment for recurrence included surgery (n = 5, 100%), chemotherapy (n = 3, 60%), and/or radiotherapy (3, 60%). Radiotherapy was used in six (50%) of the 12 patients with survival > 2 years as adjuvant primary therapy or treatment for recurrent disease, compared with three (9%) of the 35 patients with survival < 2 years (p = 0.005). With a median follow up of 53 months (range, 25-211), eight patients (67%) were alive without disease, two (17%) alive with disease and two (17%) have died of the disease 25 and 35 months from diagnosis. Conclusions: Our findings suggest that prolonged survival can be achieved in patients with SCCOHT, even with advanced stage disease. Radiotherapy may play an important role in the management of this disease. Molecular characterization of the tumors from these patients with prolonged survival is under development.